CA2708489A1 - Utilisation de cabazitaxel et de prednisone ou de prednisolone pour traiter le cancer de la prostate - Google Patents

Utilisation de cabazitaxel et de prednisone ou de prednisolone pour traiter le cancer de la prostate Download PDF

Info

Publication number
CA2708489A1
CA2708489A1 CA2708489A CA2708489A CA2708489A1 CA 2708489 A1 CA2708489 A1 CA 2708489A1 CA 2708489 A CA2708489 A CA 2708489A CA 2708489 A CA2708489 A CA 2708489A CA 2708489 A1 CA2708489 A1 CA 2708489A1
Authority
CA
Canada
Prior art keywords
cabazitaxel
patient
prostate cancer
patients
prednisone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CA2708489A
Other languages
English (en)
Inventor
Sunil Gupta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Publication of CA2708489A1 publication Critical patent/CA2708489A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2708489A 2009-10-29 2010-06-23 Utilisation de cabazitaxel et de prednisone ou de prednisolone pour traiter le cancer de la prostate Withdrawn CA2708489A1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US25616009P 2009-10-29 2009-10-29
US61/256.160 2009-10-29
US29390310P 2010-01-11 2010-01-11
US61/293.903 2010-01-11
US35583410P 2010-06-17 2010-06-17
US61/355.834 2010-06-17

Publications (1)

Publication Number Publication Date
CA2708489A1 true CA2708489A1 (fr) 2011-04-29

Family

ID=43923126

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2708489A Withdrawn CA2708489A1 (fr) 2009-10-29 2010-06-23 Utilisation de cabazitaxel et de prednisone ou de prednisolone pour traiter le cancer de la prostate

Country Status (2)

Country Link
CN (2) CN106309452A (fr)
CA (1) CA2708489A1 (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2859996B1 (fr) * 2003-09-19 2006-02-03 Aventis Pharma Sa Solvat acetonique du dimethoxy docetaxel et son procede de preparation
TW200719903A (en) * 2005-04-19 2007-06-01 Combinatorx Inc Compositions for the treatment of neoplasms

Also Published As

Publication number Publication date
CN106309452A (zh) 2017-01-11
CN104784187A (zh) 2015-07-22

Similar Documents

Publication Publication Date Title
US10716777B2 (en) Antitumoral use of cabazitaxel
EP3076972B1 (fr) Traitement du cancer avec une association de plinabuline et de taxane
Malhotra et al. Cabazitaxel: A novel drug for hormone-refractory prostate cancer
CN101257921A (zh) 使用卡奇霉素-抗体偶联物与zosuquidar的组合治疗癌症患者
AU2015200149B2 (en) Novel antitumoral use of cabazitaxel
CA2708489A1 (fr) Utilisation de cabazitaxel et de prednisone ou de prednisolone pour traiter le cancer de la prostate
EP3808345A1 (fr) Cabazitaxel chez des patients atteints d'un cprcm précédemment traités avec du docétaxel et qui ont résisté à un traitement antérieur impliquant un agent inhibiteur ciblé de la signalisation d'androgène
JP2018516890A (ja) がん治療のためのカバジタキセルおよびその使用
RU2519186C2 (ru) Производное соединение холестанола для комбинированного применения
UA110606C2 (uk) Нове протипухлинне застосування кабазитакселу
WO2015104417A1 (fr) Utilisation du cabazitaxel pour le traitement de l'adénocarcinome gastrique

Legal Events

Date Code Title Description
EEER Examination request
AZWI Withdrawn application

Effective date: 20180523